Why an American Pays $969 and a German €59 for the Same Ozempic Pen
Ozempic, the once-weekly injectable pen that propelled Novo Nordisk to become one of Europe’s most valuable companies, carries a staggering price disparity across the Atlantic. In the United States, the list price for a month’s supply hovers around $969, while in Germany, the identical pen filled with semaglutide sells for approximately €59 through statutory health insurance. The molecule inside is the same, often manufactured in the same Danish factory in Kalundborg. This vast difference in pricing is among the largest seen globally for any prescription drug, and its roots trace back to a century-old rescue mission involving a Danish Nobel laureate.
In May 2026, the White House formally acknowledged this pricing gap in its Most-Favored-Nation (MFN) drug pricing framework, highlighting that American patients routinely pay three to ten times more than those in peer countries for identical branded medications. Ozempic and its counterpart Wegovy rank near the top of this list, underscoring the urgency of addressing drug affordability in the U.S.
But how did a Danish injectable come to cost an American nurse more than her car payment? The answer begins with an extraordinary event in Toronto in 1922.
The Rescue in Toronto, 1922
Fourteen-year-old Leonard Thompson was near death from diabetes at Toronto General Hospital when Frederick Banting and Charles Best administered the first injection of pancreatic extract in January 1922. Although the initial dose was impure and caused an abscess, a second, purified version prepared by biochemist James Collip saved Thompson’s life, allowing him to survive for years thereafter.
Banting and John Macleod were awarded the Nobel Prize in Medicine in 1923, with Banting sharing his prize money with Best and Macleod sharing his with Collip. In a remarkable act of generosity, the team sold the insulin patent to the University of Toronto for a nominal fee, driven by Banting’s conviction that insulin “belonged to the world.”
At the same time, August Krogh, a Danish physiologist and Nobel laureate, observed the breakthrough from afar. His wife Marie suffered from diabetes, prompting the Kroghs to travel to North America in 1922 to secure a license to produce insulin in Scandinavia. This license laid the foundation for Nordisk Insulinlaboratorium, which later merged with Novo to form the modern pharmaceutical giant Novo Nordisk.
A Foundation, Not a Family
From its inception, Nordisk was structured as a non-profit entity, with shares held by a foundation mandated to reinvest surplus profits into diabetes research or public health initiatives. After merging with Novo, the newly formed company retained this unique ownership model. Today, the Novo Nordisk Foundation holds the controlling voting stake in the company and ranks among the world’s largest philanthropic foundations by asset value.
This distinctive Danish corporate form, with no direct American equivalent, fundamentally shapes Novo Nordisk’s drug pricing philosophy in its home market. Across Denmark and much of Europe, semaglutide is primarily viewed as a diabetes therapy and a public good—a molecule handed off for a dollar over a century ago.
What Semaglutide Actually Does
Semaglutide is a GLP-1 receptor agonist—a synthetic analogue of a gut hormone released after eating. This hormone signals the pancreas to secrete insulin, instructs the liver to suppress glucose production, and importantly, communicates to the brain that the stomach is full. GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound mimic this hormone and remain active in the bloodstream for days rather than minutes.
Initially, weight loss was considered a side effect of these medications. However, clinical trials revealed that patients on higher doses experienced significant weight reduction. Cardiovascular outcome studies also demonstrated fewer heart attacks and strokes, while kidney trials showed reduced renal decline. Semaglutide evolved from a diabetes treatment into a broader metabolic reset therapy.
By 2026, according to Forbes Health’s GLP-1 statistics, approximately 1 in 8 American adults had tried a GLP-1 medication, with tens of millions of prescriptions filled annually.
The $969 Pen and the €59 Pen
Geography plays a defining role in drug pricing. In the United States, the list price for a 1-mg monthly supply of Ozempic stands at $968.52. Wegovy, the higher-dose version approved specifically for weight loss, commands an even steeper price. While many Americans with commercial insurance pay less due to rebates and copays, uninsured patients or those whose plans exclude weight-loss drugs face costs close to the sticker price.
Conversely, in Germany, statutory health insurance reimburses the same 1-mg Ozempic pen at about €59 for a monthly supply. France and the UK similarly maintain significantly lower prices. In Denmark, where the drug is manufactured, prices are even more affordable.
The active ingredient is bioequivalent across these markets, with Novo Nordisk’s Kalundborg facility supplying much of the global demand.
Why the Numbers Diverge
Three main factors explain the stark price differences.
First is reference pricing. European statutory insurers—such as Germany’s health funds, France’s Assurance Maladie, and the UK’s NICE—negotiate collectively on behalf of millions of patients. They set reimbursement benchmarks based on therapeutic value and refuse to pay above those limits. Novo Nordisk either accepts these prices or foregoes market access, but rarely chooses the latter.
Second is the complex U.S. Pharmacy Benefit Manager (PBM) system. PBMs like CVS Caremark, Express Scripts, and OptumRx negotiate rebates with manufacturers in exchange for favorable formulary placement. Although these rebates reduce net costs behind the scenes, they are opaque, often retained partly by PBMs, and do not lower the official list price. Uninsured patients consequently face the full sticker price at the pharmacy.
Third is the so-called innovation subsidy. The White House analysis contends that American consumers effectively underwrite global pharmaceutical research and development by paying unregulated, often higher prices, while other wealthy nations negotiate down costs. The MFN policy aims to tie U.S. drug prices to the lowest prices paid by peer countries, potentially slashing the American cost of Ozempic significantly if implemented.
The Competition Arriving
Novo Nordisk no longer holds a monopoly on the GLP-1 market. Eli Lilly’s tirzepatide—marketed as Mounjaro for diabetes and Zepbound for weight loss—targets both GLP-1 and GIP receptors and has demonstrated superior weight loss outcomes in head-to-head trials against semaglutide. By 2024, Lilly’s market capitalization surpassed Novo Nordisk’s, and by mid-2026, Lilly was racing toward a trillion-dollar valuation while Novo’s shares retreated from their 2023 highs.
In response, Novo Nordisk implemented targeted price reductions. Its direct-to-consumer NovoCare Pharmacy began offering Wegovy at $499 per month to cash-paying U.S. patients in 2025, with additional price cuts following in 2026 to defend market share. Despite these efforts, even $499 remains more than eight times the €59 price paid by a German patient through statutory insurance.
The Danish Echo
The Novo Nordisk Foundation continues to fulfill August Krogh’s vision by investing heavily in metabolic research at the University of Copenhagen, funding antibiotic resistance programs, quantum computing initiatives, and a global diabetes prevention campaign. Over its history, the foundation has donated tens of billions of Danish kroner.
Notably, the revenue underpinning these philanthropic efforts derives disproportionately from the U.S. market, where prescription volumes for GLP-1 drugs are substantial. Financial analysts tracking Novo Nordisk have warned that a U.S. price cut on the scale proposed by the MFN framework could reduce the foundation’s capacity to fund biomedical philanthropy in Europe and beyond.
This outcome underscores a complex paradox. A Canadian scientific breakthrough, donated freely in 1922, journeyed to Denmark via a physiologist striving to save his wife. It resulted in a non-profit-owned pharmaceutical powerhouse that now markets the world’s most sought-after weight-loss drug. Consequently, Americans paying $969 monthly are, indirectly, financing Danish research grants that trace back to Frederick Banting’s ethical stance against profiting from insulin.
What Leonard Thompson Would Recognize
Leonard Thompson, the boy saved by early insulin, spent his life injecting the life-saving hormone. Today’s insulin pen bears little resemblance to the glass syringe filled with pork-pancreas extract administered in 1922. Instead, it is a sleek, plastic auto-injector, roughly the size of a highlighter, containing a carefully engineered molecule—semaglutide—a reimagined gut hormone inspired by the venom of the Gila monster and engineered to remain active for a week.
Yet the cost Thompson would face today depends largely on his citizenship. A German pensioner obtains the drug for the price of a nice meal out, while an American worker without adequate insurance confronts a bill roughly sixteen times higher. The molecule is identical. The pharmacy shelf is the same. The century between Toronto and Kalundborg remains unchanged.
In the end, only the invoice reveals where you stand.
Source: Here
